Safe UV and Reactive Species levels only with the Adtec SteriPlas

As a leading medical device company, the crucial balance of safety and clinical efficacy are a top priority. We are always conducting tests to demonstrate the approved safety and reliability of the Adtec SteriPlas but to also learn new ways to improve the use of cold plasma in medicine.

 

Our clinical studies already validate the safety of the Adtec SteriPlas, including its low-level UV and reactive species produced from the cold plasma. These two components are imperative for the physical destruction of bacteria, however, too much of a good thing can also be relatively damaging like that observed with cold plasma jet/pens and battery powered cold plasma devices.

 

Measured across multiple distances, the UV light produced is well below the ICNIRP limit of 30 J/m2 and the reactive species produced are well below the occupational limits set by NIOSH and UK HSE. The Adtec SteriPlas continues to be one of the only cold plasma medical devices that puts patient and user safety first with no reported side effects and promising clinical efficacy from every treatment conducted.

For more information about the Adtec SteriPlas, send us an email at info@adtecplasma.com


Casopis Lecba ran-page-003

Did you see the Adtec SteriPlas featured in the Czech Society for Wound Healing magazine?


Dr Hokynková from the Department of Burns and Plastic Surgery at Brno Hospital in Czech Republic had published a case study in the magazine to document the efficacy of the Adtec SteriPlas after having tested this on a variety of wounds including pressure ulcers and diabetic foot ulcers.

 

The article validates the SteriPlas’ ability to significantly reduce microbial load within the wound which allows the body to regain control and accelerate healing of stalled wounds. This includes wounds that are already contaminated with biofilm and listed for amputations. A change from the conventional therapies already existing on the market, the Adtec SteriPlas has proven to reverse further deterioration of complicated wounds and allow full healing and stability to be achieved.

 

For a translation of the article or to learn more about our efficacy and treatment options, please email us at info@adtecplasma.com

 


LVAD - Heidelberg publication 2021

 

Congratulations to Dr Kremer and the Cardiology Team at The University Hospital Heidelberg for their new publication, “Follow-Up after Cold Atmospheric Argon Plasma for Wound Management of Driveline Infections - A Promising Strategy”. This publication features the use of our Adtec SteriPlas medical device for the treatment of driveline infections (DLI). The results demonstrate how the safety, reliability and painless treatment from the Adtec SteriPlas can significantly reduce the wound and infection around the DLI, with the opportunity for sustainable freedom from DLI.


The SteriPlas sets foot in the U.S.A.

We are excited to share news of our collaboration with The Southern Illinois University in United States of America. Our Adtec SteriPlas will be used as part of their study to examine the effect of cold plasma on a variety of infection burn model cases in a research laboratory setting. This study aims to help tackle the outbreaks of antimicrobial resistant microorganisms that continues to be an issue for burns cases. We look forward to providing more information and the results as the study progresses.


Deep Sternum Surgical Site Infections (DSSIs)

 

Deep sternal surgical site infections (DSSIs) are a still a severe complication after cardiac surgery. The mortality estimated range is between 15%-40% of all cases. In addition to the significantly extended hospitalization, there is a significant cost burden with a calculated cost of € 36,000 for a single DSSI case.

The use of the Adtec SteriPlas for these complicated conditions has been actively documented as better managing the chronic infections, reducing hospitalization times and cost but more importantly it has shown to decrease the mortality rate. Our medical device has been praised as a tissue and life saving medical device.


Patient and user safety is priority with the Adtec SteriPlas

As a medical device company, we always strive to ensure the priority of patient and user safety. In comparison to battery-powered and smaller cold plasma devices which may produce unreliable and damaging levels of ozone and NOx, the Adtec SteriPlas has been carefully designed as a safe and well-balanced cold plasma medical device. It has been engineered to deliver predictable levels of cold plasma to ensure the continuity of no side effects reported, putting safety and efficacy at the top priority.

 

   


New SteriPlas version and change in device Classification

Due to our proven clinical success in treating non-healing and challenging wounds, we are proud to announce the upgrade of our medical device classification to Class IIb for the Adtec SteriPlas .

This change in medical device classification also supports its continued use for treating chronic and deep wounds and surgical site infections and for treating dermatological conditions.

We also announce the product launch of a new version of our SteriPlas Version 2 model in our Cold Plasma medical device family delivering the same performance. We are very proud of the safety of our devices with no incidents or adverse events reported in 15 years of use.


SteriPlas treatment for Acne Vulgaris

We are excited to announce the recent publication, “Cold atmospheric plasma (CAP) as a promising therapeutic option for mild to moderate acne vulgaris” which features our Adtec SteriPlas cold plasma for the treatment of acne.

 

The paper created by Dr Mariachiara Arisi from the Department of Dermatology at the University of Brescia, Italy demonstrates the antibacterial efficacy of our patented cold plasma for the treatment of acne vulgaris patients. It indicates the significant reduction of acne skin lesions in treated patients who were previously unsuccessful treated with topical drugs. Unlike topical drugs, the Adtec SteriPlas demonstrated a safe, effective, and well-tolerated treatment option with no side effects for the treatment of acne patients.

 

No adverse effects or skin reactions were reported either during the treatment nor at 3-months follow-up. Treatment was completely painless and well tolerated. Patients did not report itching or burning sensation during plasma application and in the following days.

 

The full paper can be found here: https://www.sciencedirect.com/science/article/pii/S2212816620300172


Adtec Healthcare celebrates yet another RCT publication

 

Adtec Healthcare celebrates another prospective, randomized and placebo-controlled trial (RCT) publication featuring our cold plasma medical device for the treatment of chronic wounds. The clinical trial conducted at the Essen University Medical Center in Germany and led by Professor Joachim Dissemond discusses the strong benefit of using the Adtec SteriPlas to treat chronic wounds. This is our first RCT measuring wound healing rates with respect to overall wound size using cold plasma.

The study consisting of three groups (Group 1 - plasma 1x/week, Group 2- plasma 3x/week and Group 3 - placebo 1x/week) shows the significant wound size reduction when using cold plasma vs placebo. Not surprisingly, Groups 1 and 2 led an astonishing 63.0% and 46.8% reduction in wound size for chronic wound patients, whereas Group 3 (placebo-treated) patients had increased in wound size by 17.5% larger.

The full publication can be viewed here: https://onlinelibrary.wiley.com/doi/epdf/10.1111/ddg.14294

The rich data of the RCT further demonstrates why our cold plasma medical device, the Adtec SteriPlas, continues to lead the way for cold plasma medicine by accelerating healing in non-healing and problematic wounds with the strong advantage of no side effects. The use of the Adtec SteriPlas is simple – a quick supplement to your standard treatment program for your patients.

 

Contact us at info@adtecplasma.com to learn more about our medical device and how to obtain this in your clinic.


New Actinic Keratoses clinical trial publication release

Congratulations Professor Alexander Rösch and his team at the Department of Dermatology at the University Hospital Essen for their recent clinical trial publication. The study “Efficacy of cold atmospheric plasma versus diclofenac 3% gel in patients with actinic keratoses: a prospective,  randomized, and rater-blinded study (ACTICAP)” can be found here.

Their clinical trial began in 2017 and its purpose was to test the efficacy of our medical device, the Adtec SteriPlas on actinic keratoses patients in comparison to those treated with Diclofenac 3% gel. The clinical efficacy of this modality is comparable to that of Diclofenac gel. However, unlike Diclofenac, cold atmospheric plasma showed no major side effects. Thus, this modality might be especially well-suited for patients who require nontoxic treatment options, particularly immunocompromised patients and those with extensive field cancerization. This continues to be one of our strongest and most favoured characteristics of the Adtec SteriPlas: no side effects.

We encourage you to read the clinical trial publication and welcome any questions that you have.

#actinickeratoses #actinickeratosis #skin #dermatology #coldplasma #kaltesplasma #clinicaltrial #sideeffects